Crescent Capital: Why I Still Wouldn't Buy Even After The 19% Dividend Cut

Crescent Capital BDC (CCAP) cut its dividend by 19% as non-accruals rose and investment income declined. In Q1, net investment income fell to $0.38/share while non-accruals jumped to 5.7% of cost, pressuring NAV and dividend sustainability. With shares trading ~39% below NAV and a 12%+ yield still not enough to offset the risk from persistent inflation and potential further credit deterioration.

Analysis

CCAP screens cheap for a reason: in BDCs, discount-to-NAV is only actionable if NAV is stable and income coverage is durable. Once non-accruals rise into a meaningful share of the book, the market typically stops valuing the reported NAV as a hard floor and starts discounting the probability of another mark-down or dividend reset.

The more important second-order effect is peer differentiation. Higher-quality BDCs with tighter underwriting and lower non-accrual burdens should attract incremental capital as yield investors rotate out of perceived traps; that can support relative multiples for names like ARCC and BXSL even if the broader BDC complex stays range-bound. If credit conditions stay sticky, the pressure is not just on CCAP’s equity value but also on its funding flexibility, since weaker coverage can translate into less access to attractive liability terms and more expensive capital replacement.

The key catalyst path is 1-3 months: another quarter of weak NII or elevated non-accruals would likely force the market to price in a further dividend cut or NAV revision. Over 6-18 months, the thesis only improves if inflation cools enough to relieve borrower stress and floating-rate debt service, but that is a slow unwind; until then, “high yield” BDCs can continue to be value traps. The contrarian argument is that the discount is already severe, but I’d want evidence of improving accruals before treating it as mispriced rather than deserved.

Key Decisions for Investors

• Short CCAP on any relief rally; use a 1-3 month horizon and look for downside continuation if the market starts pricing a second dividend cut or NAV reset. Falsifier: a clear rebound in NII coverage and a meaningful decline in non-accruals next quarter.
• Pair trade: long ARCC or BXSL vs short CCAP, sized dollar-neutral, to isolate credit-quality dispersion within BDCs. Target is 10-15% relative underperformance from CCAP if risk sentiment stays stable.
• Avoid using the headline discount-to-NAV as a bottom-fishing signal in CCAP until management proves the non-accrual rate is peaking. If you want exposure to BDC income, rotate into higher-quality names rather than averaging down here.
• Watch BIZD and the broader BDC basket for spillover only if CCAP’s weakness spreads into peers; absent that, this looks idiosyncratic rather than sector-wide.